2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3738 Longitudinal ADAR1 expression identifies stem cell evolution beyond driver mutation vaf monitoring in myeloproliferative neoplasms

Inge Van Der Werf, PhD, Claire Engstrom2, Kendale Wirtjes3, Emma E Klacking, BS4, Athena Mohebbi5, Jessica Pham6, Peter Redublo7, Thomas Whisenant, PhD8, Ludmil Alexandrov9, Sheldon Morris10, Catriona Jamieson, MD, PhD11
1 University of California San Diego, La Jolla, California, United States
2 University of California San Diego, La Jolla, California, United States
3 University of California San Diego, La Jolla, California, United States
4 University of California San Diego, La Jolla, California, United States
5 University of California San Diego, La Jolla, California, United States
6 University of California San Diego, La Jolla, California, United States
7 University of California San Diego, La Jolla, California, United States
8 University of California, San Diego, La Jolla, United States
9 University of California, San Diego, La Jolla, United States
10 University of California San Diego, La Jolla, California, United States
11 University of California San Diego, La Jolla, California, United States

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC)–derived disorders that can evolve into acute myeloid leukemia (AML) at variable rates. Although JAK2 inhibitor therapies have improved outcomes, and variant allele frequency (VAF) monitoring informs therapeutic response, genomic alterations alone do not capture functional changes in pre-leukemic stem cells (pre-LSCs) that precede malignant transformation. Emerging evidence suggests that macro-environmental, micro-environmental and cellular stressors can induce retrotransposon derepression and activate stress-responsive RNA-editing enzymes, including ADAR1 and APOBEC3C, potentially reshaping HSC fitness. Here, we hypothesize that stress-responsive retrotransposon and RNA-editing signatures present a previously unrecognized layer of MPN evolution that captures functional changes in pre-LSCs beyond conventional genomic monitoring.

We developed a longitudinal multi-omics framework integrating 150-gene NGS-based genomic monitoring, single-cell RNA sequencing, and functional stem cell assays in patients with MPN. From a cohort of 121 patients undergoing serial molecular profiling, we identified four individuals treated with JAK2 inhibition followed by allogeneic stem cell transplantation with available longitudinal cryopreserved peripheral blood and bone marrow specimens, spanning 15, 17, 24, and 31 sequential time points collected between 2013 and 2025. Single-cell RNA sequencing of paired longitudinal CD34⁺-enriched biospecimens (165,352 cells) revealed expansion of an ADAR1-high HSC population immediately prior to transplantation across all four patients. This population was characterized by enrichment of interferon-α and interferon-γ signaling, with additional patient-specific activation of TNFα/NF-κB, MYC target, IL2–STAT5, and IL6–JAK–STAT3 pathways. Longitudinal qPCR analysis confirmed progressive increases in ADAR1 expression across serial time points despite stable driver mutation VAF, whereas APOBEC3C, JAK2, and STAT3 demonstrated greater interpatient variability. Functional colony-forming assays further demonstrated increased clonogenic capacity at time points associated with elevated ADAR1 expression.

These findings reveal that RNA-editing-associated inflammatory signatures capture a dynamic layer of stem cell evolution and clonal fitness that is not reflected by driver mutation VAF, supporting their potential as complementary biomarkers for monitoring MPN progression, guiding therapeutic decision-making, and predicting transformation to secondary AML.

Inge Van Der Werf, PhD: No relevant conflicts of interest to declare.